Hims & Hers Health (NYSE:HIMS) Research Coverage Started at Evercore ISI

Evercore ISI began coverage on shares of Hims & Hers Health (NYSE:HIMS) in a research report sent to investors on Monday morning, MarketBeat reports. The firm issued an in-line rating and a $33.00 price target on the stock.

A number of other equities research analysts have also weighed in on HIMS. Barclays started coverage on Hims & Hers Health in a report on Monday, December 8th. They issued an “overweight” rating and a $48.00 price objective on the stock. Bank of America lifted their price target on Hims & Hers Health from $28.00 to $32.00 and gave the company an “underperform” rating in a research note on Tuesday, November 4th. BTIG Research reiterated a “buy” rating and issued a $85.00 price objective on shares of Hims & Hers Health in a research report on Tuesday, November 4th. Wall Street Zen lowered shares of Hims & Hers Health from a “hold” rating to a “sell” rating in a research report on Saturday, November 8th. Finally, Weiss Ratings reiterated a “hold (c)” rating on shares of Hims & Hers Health in a report on Monday, December 29th. One research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, eleven have issued a Hold rating and three have given a Sell rating to the company’s stock. According to MarketBeat.com, Hims & Hers Health has an average rating of “Hold” and an average price target of $44.54.

Hims & Hers Health Price Performance

Hims & Hers Health stock opened at $31.39 on Monday. The company has a debt-to-equity ratio of 1.67, a current ratio of 1.88 and a quick ratio of 1.64. The business has a 50 day simple moving average of $36.19 and a 200-day simple moving average of $45.92. Hims & Hers Health has a 12 month low of $23.97 and a 12 month high of $72.98. The stock has a market capitalization of $7.15 billion, a PE ratio of 58.13, a price-to-earnings-growth ratio of 5.46 and a beta of 2.37.

Hims & Hers Health (NYSE:HIMS) last announced its quarterly earnings data on Monday, November 3rd. The company reported $0.06 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.09 by ($0.03). Hims & Hers Health had a net margin of 6.05% and a return on equity of 24.67%. The firm had revenue of $598.98 million during the quarter, compared to analyst estimates of $578.99 million. During the same period in the prior year, the firm posted $0.32 earnings per share. The business’s quarterly revenue was up 49.2% compared to the same quarter last year. Equities analysts predict that Hims & Hers Health will post 0.29 earnings per share for the current year.

Hims & Hers Health declared that its Board of Directors has initiated a share repurchase program on Monday, November 17th that allows the company to buyback $250.00 million in shares. This buyback authorization allows the company to buy up to 3% of its stock through open market purchases. Stock buyback programs are usually an indication that the company’s management believes its stock is undervalued.

Insider Buying and Selling at Hims & Hers Health

In other Hims & Hers Health news, COO Michael Chi sold 13,750 shares of the firm’s stock in a transaction on Wednesday, December 17th. The stock was sold at an average price of $36.71, for a total transaction of $504,762.50. Following the completion of the transaction, the chief operating officer owned 305,161 shares of the company’s stock, valued at approximately $11,202,460.31. This trade represents a 4.31% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, insider Deborah M. Autor sold 7,054 shares of the company’s stock in a transaction on Wednesday, December 17th. The shares were sold at an average price of $36.71, for a total value of $258,952.34. Following the completion of the sale, the insider owned 6,175 shares in the company, valued at $226,684.25. This represents a 53.32% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders sold 137,136 shares of company stock worth $5,283,072. 13.71% of the stock is currently owned by insiders.

Institutional Trading of Hims & Hers Health

Hedge funds have recently bought and sold shares of the company. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its holdings in Hims & Hers Health by 23.1% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 418,699 shares of the company’s stock valued at $12,373,000 after buying an additional 78,543 shares during the period. Geneos Wealth Management Inc. purchased a new stake in shares of Hims & Hers Health during the 1st quarter worth about $30,000. Strs Ohio acquired a new stake in Hims & Hers Health during the 1st quarter worth approximately $1,469,000. Parallel Advisors LLC increased its position in Hims & Hers Health by 175.0% during the 2nd quarter. Parallel Advisors LLC now owns 1,155 shares of the company’s stock worth $58,000 after purchasing an additional 735 shares in the last quarter. Finally, Webster Bank N. A. raised its holdings in Hims & Hers Health by 229.1% in the second quarter. Webster Bank N. A. now owns 905 shares of the company’s stock valued at $45,000 after buying an additional 630 shares during the period. Institutional investors and hedge funds own 63.52% of the company’s stock.

About Hims & Hers Health

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.